Evidence-aware
Safety focused
Women’s Health Clinic FAQ
Are intimate polynucleotides hormone-free?
Intimate polynucleotides are non-hormonal biostimulatory treatments used in some clinics for vulvovaginal tissue quality. The key decision is whether the symptom has been properly assessed first.
Direct answer
Yes. Intimate polynucleotides are hormone-free; they are purified DNA fragments, usually fish-derived, used as a biostimulatory injectable rather than ooestrogen therapy. They are intended to support local tissue repair, hydration and extracellular-matrix activity, not to change systemic hormone levels. That can make them relevant for some patients seeking non-hormonal options, but suitability still depends on diagnosis, allergy history, infection screening and medical review.
The safest plan starts by clarifying the symptom, checking red flags, explaining alternatives and agreeing realistic expectations before any procedure is booked.
Educational only. Suitability must be confirmed after consultation and assessment. Results vary. Not a cure.
At a glance
These are the main points to understand before deciding whether this option is suitable.
Polynucleotides at a glance
Non-hormonal biostimulation
Composition
Highly purified DNA fragments, typically derived from the sperm cells of salmon or trout .
Mechanism of Action
They act as biological messengers that stimulate fibroblast cells, encouraging the natural production of collagen, elastin, and hyaluronic acid within.
Core Indications
They are used to treat Genitourinary Syndrome of Menopause (GSM), addressing symptoms like vaginal dryness, itching, tissue fragility, laxity, and.
Safety Profile
They offer a highly biocompatible, non-surgical, and non-hormonal alternative to traditional Hormone Replacement Therapy (HRT) .
Important safety note
General Safety: Polynucleotides are highly purified and biocompatible, making severe adverse reactions or true allergic responses extremely rare .
Allergy
Technique
Timeline
Aftercare
Detailed answer
How polynucleotides fit into intimate care
Polynucleotides are best explained as biostimulatory DNA fragments rather than fillers. The clinical question is whether they match the diagnosis, tissue findings and safety profile.
Not a standard filler
The aim is gradual tissue-quality support through repair signalling, hydration and extracellular-matrix activity, not instant volume or a promised sexual-function outcome.
Evidence
Symptoms
Alternatives
What it means
Synergistic Formulations: Products designed for intimate areas (e.g., NewGyn) frequently combine Polynucleotides High Purification Technology (PN-HPT) with non-crosslinked hyaluronic acid and mannitol to provide immediate deep hydration while long-term tissue.
Why it happens
Oncology Patients: Because they are hormone-free, polynucleotides are an excellent, potentially useful option for breast cancer survivors or patients experiencing severe iatrogenic (treatment-induced) menopause following chemoradiotherapy who are contraindicated for.
Evidence limits
Non-Volumizing: Unlike traditional crosslinked dermal fillers, polynucleotides do not simply add artificial volume or "bulk"; they focus on regenerating the actual quality, thickness, and elasticity of the mucosal tissue .
Treatment fit
Procedure Time: The treatment is relatively quick, generally taking between 10 to 45 minutes to complete in a clinical setting .
What this means in practice
Procedure Time: The treatment is relatively quick, generally taking between 10 to 45 minutes to complete in a clinical setting .
Treatment Course: A standard initial protocol generally requires 3 to 5 sessions, spaced 2 to 4 weeks apart (or 7 to 14 days depending on the specific product protocol) .
Patient safety
Why diagnosis comes first
Dryness, soreness, tearing or painful sex may reflect GSM, infection, dermatoses, pelvic-floor guarding or medication effects, so the treatment choice depends on assessment.
It checks the cause
Synergistic Formulations: Products designed for intimate areas (e.g., NewGyn) frequently combine Polynucleotides High Purification Technology (PN-HPT) with non-crosslinked hyaluronic acid and mannitol to provide.
It protects safety
General Safety: Polynucleotides are highly purified and biocompatible, making severe adverse reactions or true allergic responses extremely rare .
It reviews alternatives
Procedure Time: The treatment is relatively quick, generally taking between 10 to 45 minutes to complete in a clinical setting .
It sets expectations
Treatment Course: A standard initial protocol generally requires 3 to 5 sessions, spaced 2 to 4 weeks apart (or 7 to 14 days depending.
Non-hormonal does not mean automatic
A hormone-free treatment may still be unsuitable if there is active infection, unexplained bleeding, pregnancy, recent surgery, severe fish allergy or unclear pelvic pain.
The consultation should cover product source, allergy risk, alternatives such as moisturisers or local hormonal care, and realistic timelines for tissue response.
Considerations
What to consider
Procedure Time: The treatment is relatively quick, generally taking between 10 to 45 minutes to complete in a clinical setting .
Consultation priorities
Initial Consultation: The journey begins with a thorough, discreet clinical assessment to discuss symptoms, medical history, and aesthetic or functional goals .
Consent
Aftercare
Follow-up
Before treatment
Initial Consultation: The journey begins with a thorough, discreet clinical assessment to discuss symptoms, medical history, and aesthetic or functional goals .
During care
The Procedure: The clinician cleanses the area and administers multiple small, superficial intradermal or mucosal injections precisely targeted at the areas of dryness or atrophy .
Aftercare
Recovery Phase: Patients can usually return to light daily activities immediately, navigating only minor localised swelling or tenderness for a day or two .
When to reassess
Long-Term Experience: Over subsequent weeks, patients frequently report a dramatic reduction in irritation and dyspareunia, restoring comfort, intimacy, and overall quality of life .
Practical expectations
Treatment Course: A standard initial protocol generally requires 3 to 5 sessions, spaced 2 to 4 weeks apart (or 7 to 14 days depending on the specific product protocol) .
Preparation: Hair removal in the treatment area is usually required prior to the procedure .
Common concerns and myths
Common misconceptions
Clear patient information should correct over-simple claims and keep expectations realistic.
Myth: polynucleotides are fillers
Reality: they are biostimulatory DNA fragments, usually used for gradual tissue-quality support rather than volume.
Myth: hormone-free means suitable for everyone
Reality: allergy, infection, bleeding, pregnancy, recent surgery and unexplained pain can still make treatment unsuitable.
Myth: hydration means instant repair
Reality: hydration may be noticed earlier, but collagen and tissue-quality changes are gradual and variable.
Evidence and limits
Mechanism-of-action language should not be treated as proof of a predictable clinical result.
Alternatives still matter
Moisturisers, local hormonal care, pelvic-floor physiotherapy, infection treatment or specialist review may be more appropriate for some patients.
Safety checklist
Safety checklist
Use these questions to decide whether treatment should be discussed, delayed or redirected.
Has the cause been assessed?
Symptoms should be reviewed in context before selecting a treatment.
Are red flags absent?
Do not claim intimate polynucleotides cure dryness, laxity, sexual dysfunction, pelvic symptoms, scarring or menopause-related tissue change. Explain that PN products are often fish/marine-derived and allergy history matters.
Are alternatives clear?
Procedure Time: The treatment is relatively quick, generally taking between 10 to 45 minutes to complete in a clinical setting .
Is follow-up planned?
The clinic should explain aftercare, review timing and when to seek help.
Reassuring signs
Proceeding is more reasonable when goals are clear, red flags have been checked, and expectations are realistic.
No red flags
Follow-up plan
Reasons to pause
Pause treatment for active infection, unexplained bleeding, severe fish allergy, pregnancy, recent pelvic surgery or severe pain that has not been assessed.
Bleeding
Infection
When to escalate
When to seek medical help
Some symptoms should be assessed before any elective intimate treatment. Use NHS 111 online
Allergy symptoms
Swelling of the lips or tongue, breathing difficulty, widespread hives, faintness or collapse after exposure needs urgent medical help.
Bleeding or infection
New post-menopausal bleeding, unusual discharge, fever, pelvic pain, thrush, BV or UTI symptoms should be assessed before injectable treatment.
Infection signs
Common Side Effects: Patients may experience mild, transient side effects such as localised redness, minor bruising, tenderness, and slight swelling at the injection sites, which typically resolve within.
Emergency symptoms
Call 999 in a life-threatening emergency, including collapse, chest pain or breathing difficulty.
Use NHS 111 for urgent advice or call 999 in a life-threatening emergency. This page is educational and does not replace individual medical assessment.
Regulatory resources
Authoritative resources
These sources support cautious, assessment-led patient information and help separate clinical evidence from promotional claims.
PubMed: PN/HA intradermal injections for vulvovaginal atrophy
This pilot study is directly relevant to polynucleotide and hyaluronic acid use in vulvovaginal atrophy.
Real-world study of polynucleotide-based vaginal ovules
This source supports cautious discussion of PN-based vaginal ovules, hydration and atrophy-related symptoms.
NHS guidance on allergies
NHS allergy guidance supports screening and urgent escalation language for fish-derived products.
Next step
Book a clinical consultation
A consultation can confirm whether this treatment may be suitable, whether another pathway should come first, and what realistic outcomes, risks and aftercare would look like.
▶ View Research Sources (12 Sources)
These 12 source names are selected from 24 display-ready sources, with a raw audit trail of 64 imported records. Additional reviewed material included professional society guidance; duplicate, low-relevance and non-clinical records were removed before display.
Educational only. This information is for education only and is not a substitute for professional medical advice, diagnosis or treatment. Results vary. Not a cure.
